The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.

Eur J Cancer · 2018 · PMC7493695 · PMID 29274618

Europe PMC DOI

hedged sentence

0.0712

closest p · 1.4× alpha

0.0712

boldest claim

The sentences

did not reach statistical significanceP = 0.0712so close (0.05 < p ≤ 0.1)

OS was longer for patients with wild-type KRAS than for those with mutant KRAS in both the trifluridine/tipiracil and placebo arms overall and among all regions; HRs for OS favoured trifluridine/ tipiracil over placebo regardless of KRAS status, although this benefit for patients with mutant KRAS did not reach statistical significance (P = 0.0712).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.